PET-MR: Identifying Applications for New Technology

TOHETI funding has enabled a new £3.3 million PET-MR scanner to be installed at Guy’s and St Thomas’

What is PET-MR? As Andrew Mallia, TOHETI Clinical Research Fellow for PET/MR explains:

“PET/MRI is a new hybrid imaging modality, which maximizes diagnostic information by unifying the excellent anatomical (i.e. what cells look like) information from Magnetic Resonance Imaging (MRI), and the metabolic information (i.e. what cells are doing) from PET (positron emission tomography) scans.”

Several research studies are already underway around new clinical applications for PET-MR, with others still being developed or awaiting ethics approval:

PATHWAY study - this study aims to recruit 220 patients from 11 tumour groups for direct comparison between PET/MR and PET/CT to determine which groups might benefit from direct access to PET/MR.

FIREARC study – this study assesses the utilisation of PET/MR in the assessment of therapy response in patients with primary rectal carcinoma. Earlier assessment of cancer therapy will help discontinue ineffective treatments, eliminating the risk of side effects and morbidity, and enable alternative treatments to be tested.